Free Trial

Wellington Management Group LLP Makes New $923,000 Investment in Novavax, Inc. (NASDAQ:NVAX)

Novavax logo with Medical background

Wellington Management Group LLP bought a new stake in Novavax, Inc. (NASDAQ:NVAX - Free Report) in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm bought 73,115 shares of the biopharmaceutical company's stock, valued at approximately $923,000.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Banque Cantonale Vaudoise increased its holdings in shares of Novavax by 500.0% during the second quarter. Banque Cantonale Vaudoise now owns 3,000 shares of the biopharmaceutical company's stock valued at $38,000 after acquiring an additional 2,500 shares in the last quarter. Amalgamated Bank increased its stake in Novavax by 26.9% during the 2nd quarter. Amalgamated Bank now owns 4,887 shares of the biopharmaceutical company's stock valued at $62,000 after purchasing an additional 1,036 shares in the last quarter. Signaturefd LLC raised its holdings in Novavax by 214.5% during the second quarter. Signaturefd LLC now owns 5,680 shares of the biopharmaceutical company's stock worth $72,000 after buying an additional 3,874 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Novavax by 38.1% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,790 shares of the biopharmaceutical company's stock valued at $77,000 after buying an additional 1,598 shares in the last quarter. Finally, Midland Wealth Advisors LLC acquired a new position in shares of Novavax during the second quarter valued at about $152,000. 53.04% of the stock is owned by institutional investors.

Novavax Stock Up 0.2 %

Novavax stock traded up $0.02 during mid-day trading on Friday, reaching $8.70. 6,086,848 shares of the company's stock were exchanged, compared to its average volume of 9,218,745. The firm has a market capitalization of $1.39 billion, a PE ratio of -3.85 and a beta of 2.02. The business's fifty day simple moving average is $9.21 and its 200 day simple moving average is $12.00. Novavax, Inc. has a one year low of $3.53 and a one year high of $23.86.

Novavax (NASDAQ:NVAX - Get Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.76) earnings per share for the quarter, topping analysts' consensus estimates of ($0.83) by $0.07. The company had revenue of $84.51 million during the quarter, compared to analysts' expectations of $65.80 million. During the same period last year, the firm posted ($1.26) earnings per share. Novavax's quarterly revenue was down 54.8% compared to the same quarter last year. On average, sell-side analysts forecast that Novavax, Inc. will post -1.44 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms recently weighed in on NVAX. B. Riley restated a "buy" rating and issued a $26.00 target price (up previously from $23.00) on shares of Novavax in a report on Thursday, October 10th. Jefferies Financial Group lowered their price objective on Novavax from $31.00 to $25.00 and set a "buy" rating for the company in a research note on Wednesday, October 16th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $19.00 target price on shares of Novavax in a research report on Tuesday, December 10th. One analyst has rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average price target of $17.83.

Read Our Latest Stock Analysis on Novavax

Novavax Profile

(Free Report)

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.

Featured Articles

Institutional Ownership by Quarter for Novavax (NASDAQ:NVAX)

Should You Invest $1,000 in Novavax Right Now?

Before you consider Novavax, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novavax wasn't on the list.

While Novavax currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Crypto Boom 2025: Bitcoin’s Rise and Trump’s Impact on the Market
Goldman Sachs’ 2025 Market Outlook: Top 3 Stock Picks
7 Stocks to Benefit From Trump’s Tariffs in 2025

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines